Cyclin/CDK complexes belong to a serine/threonine protein kinase family and play key roles as the positive regulators in cell cycle progression1^Overexpression of cyclins or CDKs,and loss or decreased level of endogenous CDKinhibitor proteins such as pi6 and p27 in various tumors have been reported2). Flavopiridol, a specific small molecule-CDK inhibitor, showed potent antitumor activity in a series of experimental tumor models and is currently in clinical trial3). Thus, the CDKs are considered as new molecular targets for cancer chemotherapy. Weestablished a novel cell-based assay using the budding yeast in which Xenopus cyclin Al was induced and then CDK(Cdc28) kinase activity was elevated4'5). The hyper-activation of CDK in yeast resulted in showing growth arrest phenotype4). The compounds which can rescue the cyclin A1-induced growth arrest might be the new antitumor drug candidates acting on the cyclin/CDK-mediated cell cycle regulation.
In the course of our microbial screening program, a novel Streptomyces metabolite belactosin A was identified as an active compoundby which regrowth of the growth-arrested yeast was induced. Isolation, physicochemical properties and biological activity of belactosin A are described.
The producing organism KYI 1780 was isolated from a soil sample collected in Kanagawa prefecture, Japan and assigned to the Streptomyces sp. Fermentation was carried out at 28°C for 48 hours with appropriate aeration and agitation in 30-liter jar fermenters containing 15 liters of culture medium, consisting of 5% sucrose, 1.5% dry yeast extracted with water and then lyophilized. 700 mg of crude belactosin A was obtained by this purification procedure.
/-Butoxycarbonylation was effective in separating belactosin A from the hydrophilic impurities contained in the active fractions. The combined crude belactosin A was treated with di-/-butyl dicarbonate and NaHCO3in 50% aq THF followed by purification of resulting product using a silicagel column and eluting with CHC13-MeOH-AcOH (50: 1 :0.1-5: 1 :0.1) to afford 382mg of Boc-belactosin A. Deprotection with TFA gave intact belactosin A with 97% yield. The related minor products belactosin B and C were also obtained from the culture broth of KYI1780. However,the production of these minor compoundswas not reproducible under the same fermentation conditions. Physico-chemical properties are shown in Table 1 . Each bioactive product was in quite water-soluble (> 10 mg/ml).
Spectral analysis revealed that belactosin A possessed an unique structure containing a novel amino acid, 3-(2-aminocyclopropyl)-alanine (AcpAla), and a B-lactone, while belactosin C contained an ornithine instead of the AcpAla with B-lactone and belactosin B contained a cleaved B-lactone with AcpAla (Fig. 1) . Belactosin B may be generated from belactosin A during the purification process, since belactosin A can be converted to belactosin B in the presence of MeOHunder basic conditions. The details of the chemistry and structure elucidation will be reported elsewhere6). Howeverthe potency of belactosins is lower than known hours exposure. Thus, we carried out microbial screening for their ability to restore the cyclin A1-induced growth arrest in budding yeast and identified a novel natural product belactosin A which inhibited cell cycle progression of human tumor cells at G2/Mphase. The details on the modeof action and further evaluation of belactosin A will be reported elsewhere5).
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